Pull to refresh
Logo
Genentech breaks ground on $750M expansion of Hillsboro plant

Genentech breaks ground on $750M expansion of Hillsboro plant

Built World

Project doubles the Oregon site's footprint and adds drug-delivery device production for US patients

2 days ago: Genentech breaks ground on the expansion

Overview

Updated 1 hour ago

Genentech broke ground Sept. 28 on a $750 million expansion of its manufacturing campus in Hillsboro, Oregon. The project adds 211,000 square feet and nearly doubles the size of the site.

The new facility will make prefilled syringes and autoinjectors, drug-delivery devices the company now imports for United States patients. Commercial operations are planned for 2031.

The investment is part of a $50 billion commitment by Roche Group, Genentech's parent, to expand US pharmaceutical manufacturing. Oregon Governor Tina Kotek joined the groundbreaking.

Why it matters

US patients rely on imported syringes and autoinjectors; this plant shifts that production to Oregon, part of a $50B domestic manufacturing push.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$750M
Investment in Hillsboro expansion
Announced capital for the new device fill-finish facility.
250
New permanent manufacturing jobs
Roles span filling and inspection, device assembly, packaging, cold storage, and quality control.
200
Construction jobs during build
Temporary positions tied to the multi-year construction phase.
$50B
Roche US manufacturing and R&D commitment
Company-wide pledge across Genentech and its parent Roche Group.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

January 2006 September 2026

4 events Latest: 2 days ago
Tap a bar to jump to that date
  1. Genentech breaks ground on the expansion

    Latest Construction

    Gov. Tina Kotek and local officials join Genentech leaders at the ceremonial start, putting construction officially underway.

  2. Genentech announces $750M expansion

    Announcement

    The company unveils plans for a new device fill-finish facility at Hillsboro, citing a stronger domestic supply chain.

  3. Genentech adds 130,000 square feet in Hillsboro

    Investment

    The company spends $175 million to increase capacity for individualized medicines; the site then employs about 450 people.

  4. Genentech opens Hillsboro campus

    Milestone

    Genentech establishes its Oregon manufacturing site, operating in the state for two decades since.

Scenarios

1

Hillsboro plant starts commercial operations in 2031

Likely Resolves by End of 2031

Discussed by: Genentech's stated plan; the company targets 2031 for commercial operations

Construction proceeds on the planned timeline. The facility starts up in 2031 with fill-finish capacity for prefilled syringes and autoinjectors, ending US imports of those devices. Genentech hires the roughly 250 permanent manufacturing workers over the coming years.

2

Construction delays push Hillsboro start to 2032 or later

Possible Resolves by End of 2031

Discussed by: Large pharmaceutical facility builds routinely slip; the 211,000-square-foot project spans multiple years

Permitting, supply chain, or labor issues push the start of commercial operations past the end of 2031. Genentech revises its public timeline and the facility comes online in 2032 or later.

3

Oregon discloses forgivable loan terms for Genentech

Uncertain Resolves by End of 2027

Discussed by: Oregon officials confirmed the loan is under negotiation; the amount was undisclosed as of August 2026

The Governor's Office and Business Oregon finalize the incentive package. State officials announce the loan amount and terms, providing the first public accounting of what Oregon paid to secure the expansion.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

2021

Genentech 2021 Hillsboro expansion (2021)

Genentech spent $175 million adding 130,000 square feet to its Hillsboro operation, increasing capacity to produce individualized medicines. The site employed about 450 people at the time.

Then

The expansion grew the campus's manufacturing capacity.

Now

The site now employs more than 800 people and anchors Genentech's US manufacturing network.

Why this matters now

The 2026 expansion doubles down on a site Genentech has invested in repeatedly, showing its strategic value.

2026

Genentech Holly Springs, North Carolina facility (2026)

Genentech built a new manufacturing facility in Holly Springs, North Carolina, as part of the same $50 billion US investment commitment. The project recently topped out, marking the building shell complete.

Then

The facility moves toward fit-out and commissioning.

Now

It expands Genentech's US manufacturing network alongside the Hillsboro expansion.

Why this matters now

Both projects stem from the same Roche commitment and show the company's parallel push to add US capacity.

Sources

(10)